What is the 13F Pro Quality Score for RANI?

13F Pro ranks Rani Therapeutics Holdings, Inc. (RANI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RANI's current score at https://13fpro.ai/research/RANI (free sign-up required for the full ranking).

Where does 13F Pro source RANI data?

All Rani Therapeutics Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Rani Therapeutics Holdings, Inc. files with the SEC under CIK 1856725. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RANI in?

Rani Therapeutics Holdings, Inc. (RANI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RANI research updated on 13F Pro?

RANI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Rani Therapeutics Holdings, Inc.(RANI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1856725 RANI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.7M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RANI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Rani Therapeutics Holdings, Inc. (RANI), a Healthcare sector company. RANI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), Rani Therapeutics Holdings, Inc. reports quarterly revenue of $1.7M, net income of $-7.0M, free cash flow of $-6.5M. Top institutional holders of RANI by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., Samsara BioCapital,, AWM Investment Company,, based on the most recent SEC filings. RANI trades on the Nasdaq exchange and files with the SEC under CIK 1856725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RANI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rani Therapeutics Holdings, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$1.7M

Net Income

Q1 2026

$-7.0M

Free Cash Flow

Q1 2026

$-6.5M

ROIC

Q1 2026

-29.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+58.9% YoY

$1.6MFY 2025

FY21 $2.7MFY23 $0.00FY24 $1.0MFY25 $1.6M

Net Income

+1.1% YoY

$-29.7MFY 2025

FY21 $-8.3MFY23 $-34.0MFY24 $-30.0MFY25 $-29.7M

Operating Income

+28.1% YoY

$-38.3MFY 2025

FY21 $-51.6MFY23 $-66.1MFY24 $-53.3MFY25 $-38.3M

EPS (Diluted)

+57.1% YoY

$-0.45FY 2025

FY21 $-0.43FY23 $-1.33FY24 $-1.05FY25 $-0.45

Total Assets

+60.0% YoY

$58.6MFY 2025

FY21 $124.2MFY23 $57.9MFY24 $36.6MFY25 $58.6M

Total Debt

-100.0% YoY

$0.00FY 2025

FY21 $0.00FY23 $34.9MFY24 $40.0MFY25 $0.00

Op. Cash Flow

+47.3% YoY

$-18.7MFY 2025

FY21 $-32.2MFY23 $-51.2MFY24 $-35.5MFY25 $-18.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020
Revenue	$1.6M +58.9%	$1.0M	$0.00 -100.0%	$2.7M +488.1%	$462.0K
Net Income	$-29.7M +1.1%	$-30.0M +11.6%	$-34.0M -307.8%	$-8.3M	—
Operating Income	$-38.3M +28.1%	$-53.3M +19.3%	$-66.1M -28.1%	$-51.6M -211.9%	$-16.5M
EPS (Diluted)	$-0.45 +57.1%	$-1.05 +21.1%	$-1.33 -209.3%	$-0.43	—
Total Assets	$58.6M +60.0%	$36.6M -36.7%	$57.9M -53.4%	$124.2M +56.4%	$79.4M
Total Debt	$0.00 -100.0%	$40.0M +14.6%	$34.9M	$0.00 -100.0%	$3.8M
Operating Cash Flow	$-18.7M +47.3%	$-35.5M +30.7%	$-51.2M -58.9%	$-32.2M -115.5%	$-15.0M

AI Insight: RANI Financial Trends

Rani swung to positive equity in Q4 2025 after eliminating all debt, but revenue remains negligible and operating losses persist.

• Total debt fell from $42M (Q2 2024) to $0M (Q4 2025), while equity recovered from -$8M to $33M by quarter-end.

• Operating cash burn improved from -$9M (Q2 2024) to $0M (Q4 2025), though Q1 2026 reverted to -$6M burn.

• Revenue remains near zero: $0M for four consecutive quarters through Q3 2025, then $1M and $2M in latest two periods.

⚠ Net losses widened to -$10M in Q4 2025 despite debt elimination and zero operating cash burn—underlying burn acceleration.

⚠ Operating margin structure deteriorated: operating losses ranged -$7M to -$15M on near-zero revenue through Q1 2026.

AI Insight: RANI Ratio Trends

Rani remains deeply unprofitable with deteriorating returns; Q4 2025 showed zero debt but ROE fell to -124.9%.

• ROA improved from -97.7% in Q4 2024 to -54.2% in Q1 2026, suggesting reduced operating losses per unit of assets.

• D/E ratio fell to 0.00 in Q4 2025 from 20.08 in Q4 2024, indicating deleveraging or equity-only capitalization.

• ROE declined to -99.0% in Q1 2026 from -124.9% in Q4 2025, a marginal deterioration despite zero debt.

⚠ TTM ROE at -103.6% and ROA at -56.8% confirm persistent unprofitability across trailing 12 months.

⚠ Most operating and profitability metrics unavailable Q1–Q3 2025; visibility gap limits trend assessment.

Get alerted when RANI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rani Therapeutics Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RANI

RA CAPITAL MANAGEMENT, L.P.
$6.2M8,500,000 sh
Samsara BioCapital, LLC
$6.2M8,500,000 sh
AWM Investment Company, Inc.
$4.8M6,500,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.4M4,622,567 sh
SymBiosis Capital Partners, LLC
$2.7M3,667,585 sh
GROUP ONE TRADING, L.P.
$2.2M3,011,800 sh
Longaeva Partners L.P.
$1.7M2,329,459 sh
Siren, L.L.C.
$1.5M2,000,000 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$877.8K1,202,500 sh
GEODE CAPITAL MANAGEMENT, LLC
$664.1K903,298 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$6.2M	8,500,000
Samsara BioCapital, LLC	$6.2M	8,500,000
AWM Investment Company, Inc.	$4.8M	6,500,000
VANGUARD CAPITAL MANAGEMENT LLC	$3.4M	4,622,567
SymBiosis Capital Partners, LLC	$2.7M	3,667,585
GROUP ONE TRADING, L.P.	$2.2M	3,011,800
Longaeva Partners L.P.	$1.7M	2,329,459
Siren, L.L.C.	$1.5M	2,000,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$877.8K	1,202,500
GEODE CAPITAL MANAGEMENT, LLC	$664.1K	903,298

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RANI on your watchlist

Track score changes the day Rani Therapeutics Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RANI a good stock to buy?

13F Pro's AI-powered analysis of Rani Therapeutics Holdings, Inc. (RANI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RANI are available on the RANI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RANI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RANI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rani Therapeutics Holdings, Inc.'s investment landscape.